Headlands Technologies LLC Makes New $642,000 Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Headlands Technologies LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 13,418 shares of the biopharmaceutical company's stock, valued at approximately $642,000.

Several other hedge funds also recently made changes to their positions in the company. CBIZ Investment Advisory Services LLC purchased a new stake in Halozyme Therapeutics in the 4th quarter valued at approximately $29,000. Heck Capital Advisors LLC purchased a new position in Halozyme Therapeutics in the fourth quarter worth $29,000. Smartleaf Asset Management LLC lifted its holdings in Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 197 shares during the period. Venturi Wealth Management LLC purchased a new stake in shares of Halozyme Therapeutics during the 4th quarter worth $69,000. Finally, Parkside Financial Bank & Trust grew its stake in shares of Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 322 shares during the period. Institutional investors and hedge funds own 97.79% of the company's stock.

Insider Activity

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the transaction, the director now owns 38,611 shares of the company's stock, valued at $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the sale, the senior vice president now directly owns 173,756 shares in the company, valued at $10,126,499.68. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,200 shares of company stock worth $1,286,568. 2.40% of the stock is currently owned by corporate insiders.

Remove Ads

Analysts Set New Price Targets

HALO has been the topic of several research reports. HC Wainwright reissued a "buy" rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Piper Sandler boosted their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a report on Friday, January 10th. Wells Fargo & Company decreased their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Finally, Benchmark reiterated a "buy" rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $62.78.

Halozyme Therapeutics Stock Down 1.2 %

HALO stock traded down $0.74 during trading on Monday, reaching $59.03. The stock had a trading volume of 700,080 shares, compared to its average volume of 1,390,540. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The firm has a fifty day moving average price of $59.82 and a 200 day moving average price of $54.82. The company has a market capitalization of $7.29 billion, a P/E ratio of 17.08, a PEG ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 1-year low of $37.73 and a 1-year high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. The firm had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. On average, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.